The global biobanking market size was valued at USD 59.98 billion in 2025 and is projected to grow from USD 64.27 billion in 2026 to USD 113.05 billion by 2034, registering a CAGR of 7.32% during the forecast period (2026–2034). North America dominated the biobanking market with a marketshare of 34.15% in 2025.
Biobanking refers to the collection, processing, storage, and management of biological samples such as blood, tissues, DNA, and cells for research, clinical, and therapeutic applications. These repositories play a vital role in advancing precision medicine, drug discovery, regenerative medicine, and disease research by providing high-quality biological specimens and associated data.
The biobanking market demand is increasing due to the growing focus on personalized medicine, genomic research, and the rising prevalence of chronic diseases. Expanding clinical trials, increasing investments in life sciences research, and advancements in sample preservation technologies are supporting market growth. Additionally, the growing adoption of digital biobanking solutions and collaborative research initiatives is further driving industry expansion.
Download a Free Sample to Explore Detailed Market Insights
A trend in the biobanking market is the adoption of federated data networks that enable researchers to analyze biospecimen-linked datasets across multiple biobanks without transferring sensitive patient information. In 2025, the European research infrastructure BBMRI-ERIC expanded federated discovery initiatives connecting hundreds of biobank collections, supporting secure cross-border genomic and clinical research. This model improves data accessibility while maintaining privacy compliance and accelerating biomarker identification for precision medicine applications globally.
Biobanks are increasingly evolving beyond traditional sample storage by incorporating spatial multi-omics preservation strategies that capture genomic, transcriptomic, proteomic, and tissue-location data from the same specimen. This enables researchers to study cellular interactions within disease microenvironments using archived samples. Organizations including UK Biobank and major academic biorepositories are expanding protocols for preserving samples compatible with spatial biology workflows, creating high-value repositories that support next-generation oncology, neuroscience, and regenerative medicine research applications.
The biobanking market forecasts continued investment growth driven by increasing demand for precision medicine, population genomics programs, biomarker discovery, and AI-enabled biomedical research. Investors are focusing on organizations developing advanced biorepositories, genomic databases, and digital biobanking infrastructure to support next-generation drug discovery and personalized healthcare.
Key Investment and Funding Activities in Biobanking Market, 2025
Galatea Bio
USD 25 Million
In April 2025, the company secured funding to develop a global biobank focused on precision health, biomarker discovery, and multi-omics research.
University of Miami Biorepository
USD 7.6 Million
In January 2025, the University of Miami Biorepository entered into an NIH-funded expansion of advanced biorepository infrastructure and automated biospecimen storage capabilities.
Expansion of Population-scale Genomics Programs and Growing Demand for Living Cell and Organoid Biobanks Drives Market
The rapid expansion of national genomics initiatives is increasing demand for large-scale biospecimen collection, long-term storage, and linked clinical datasets. In 2025, UK Biobank completed whole-genome sequencing data for all 500,000 participants, creating one of the world's largest integrated genomic resources. Such programs require advanced biobanking infrastructure, driving investments in automated storage systems, sample processing technologies, and data management platforms, thereby accelerating biobanking market growth.
The increasing use of patient-derived organoids is a major market driver. Stem cells and living tissue models in drug development are creating demand for specialized biobanks capable of preserving viable biological materials. Unlike conventional specimen repositories, these facilities require sophisticated cryopreservation protocols and continuous quality monitoring. Pharmaceutical companies and research institutions are expanding living biobanks to improve translational research accuracy, support personalized therapeutic development, and reduce reliance on traditional animal testing models across biomedical research applications.
High Costs of Ultra-low Temperature and Limited Standardization of Pre-analytical Sample Restrain Market Expansion
Many biobanks depend on ultra-low temperature freezers, liquid nitrogen systems, and continuous environmental monitoring to preserve specimen integrity over extended periods. These infrastructures require substantial capital investment, specialized maintenance, backup power systems, and energy-intensive operations. Rising operational expenses make long-term storage economically challenging, particularly for smaller biorepositories, academic institutions, and emerging biobanking programs with limited funding resources.
Variations in sample collection, transportation, processing times, and storage protocols across institutions can significantly affect biospecimen quality and research reproducibility. Even minor differences in handling procedures may alter molecular characteristics, reducing the comparability of samples between biobanks. The absence of universally adopted pre-analytical standards creates quality inconsistencies, limiting the value of stored specimens for multicenter clinical and translational research projects.
Development of Disease-specific Longitudinal Biobanks and Commercialization of Spatial Biology Offer Growth Opportunities to Market Players
The growing focus on chronic and rare disease research is creating new growth opportunity for specialized longitudinal biobanks that repeatedly collect samples from the same patients over time. These repositories provide valuable insights into disease progression, treatment response, and biomarker evolution. Various precision medicine initiatives expanded longitudinal sample collection programs, increasing demand for advanced tracking systems, repeat-consent management, and high-quality biospecimen preservation services.
Rapid adoption of spatial transcriptomics, proteomics, and multi-omics research is creating opportunities for biobanks to offer premium, analysis-ready biospecimen collections. Researchers increasingly require samples preserved using protocols compatible with advanced molecular mapping technologies. For example, in 2025, UK Biobank expanded access to large-scale imaging and omics datasets linked to participant biospecimens, enabling broader use of high-value samples for precision medicine, oncology, and drug discovery research.
Maintaining Biospecimen Quality and Integration of Heterogeneous Clinical Challenges Biobanking Market Growth
Ensuring consistent biological integrity during long-term storage remains a major challenge for biobanks. Variations in freezing rates, storage temperatures, thawing procedures, and equipment performance can alter molecular characteristics over time. Even minor degradation may affect genomic, proteomic, or cellular analyses. Maintaining validated preservation conditions across millions of samples requires continuous monitoring, quality audits, and significant operational oversight.
Biobanks increasingly manage biospecimens linked to genomic, imaging, pathology, and electronic health record datasets. However, differences in data formats, coding standards, metadata structures, and interoperability frameworks create significant integration challenges. Inconsistent data harmonization reduces the research value of biospecimen collections and complicates large-scale multi-center studies, limiting efficient utilization of biobank resources for precision medicine applications.
Based on product & service, equipment accounted for a share of 36.70% in 2025 due to increasing deployment of automated ultra-low temperature storage systems, robotic sample retrieval platforms, and cryogenic monitoring technologies across large biorepositories. Expansion of population-scale genomics programs and multi-site biospecimen collections further increased demand for high-capacity preservation and automation infrastructure.
The services segment is expected to grow at a CAGR of around 7.89% during the forecast period, owing to rising outsourcing of sample processing, biostorage management, and biospecimen logistics by pharmaceutical and research organizations. Growing demand for specialized consent management, data annotation, and quality assurance services is also supporting segment expansion.
In 2025, human tissues accounted for a share of 34.21% in the biobanking market, by biospecimen type. This is due to their critical role in oncology research, spatial biology studies, and biomarker validation programs. Their ability to preserve disease-specific cellular architecture makes them highly valuable for translational and precision medicine research applications.
The stem cells segment is expected to grow at a CAGR of 8.25% during the forecast period, driven by increasing development of regenerative therapies, organoid research models, and personalized cell-based treatments. Rising investments in induced pluripotent stem cell repositories and advanced cryopreservation technologies are further accelerating demand.
By biobank type, physical biobanks are projected to grow at a CAGR of 8.47% during the forecast period, owing to increasing requirements for secure long-term preservation of viable tissues, cells, and clinical biospecimens. Expansion of national biobanking infrastructures and demand for standardized sample processing facilities continue to support segment growth.
The virtual biobanks segment is expected to grow at a CAGR of 8.96% during the forecast period, driven by growing adoption of federated data-sharing frameworks and cross-institutional biospecimen discovery platforms. Increasing emphasis on remote accessibility, metadata integration, and privacy-preserving research collaborations is accelerating implementation.
Therapeutic accounted for the largest application share of 34.68% in 2025 due to extensive utilization of biospecimens for target identification, treatment stratification, and precision medicine development. Increasing use of patient-derived biological materials in clinical research and therapy optimization further strengthened segment dominance.
The drug discovery segment is expected to grow at a CAGR of around 9.01% during the forecast period, driven by increasing integration of biobank samples with multi-omics datasets and AI-assisted biomarker discovery workflows. Demand for high-quality, clinically annotated biospecimens is expanding as pharmaceutical companies accelerate precision drug development programs.
North America: Market Dominance Led by Large-scale Population Biobanks and Advanced Biospecimen Automation Infrastructure
The North America biobanking market accounted for the largest regional share of 34.15% in 2025, driven by extensive deployment of automated biospecimen storage facilities, mature genomic research ecosystems, and strong integration of biobanks with precision medicine programs. The region benefits from highly standardized sample governance frameworks and large-scale repositories. For example, the US NIH-supported All of Us Research Program had enrolled more than 850,000 participants contributing biospecimens and health data by 2025, strengthening regional biobanking infrastructure.
The US biobanking market was valued at USD 18.02 billion in 2025, driven by the country's leadership in population-scale genomic initiatives and its extensive network of disease-specific biorepositories supporting oncology, neurology, and rare disease research. Strong collaboration between academic medical centers, federal research agencies, and pharmaceutical developers increases demand for high-quality biospecimens. The availability of large longitudinal datasets linked with biological samples further enhances the value of biobanking resources for translational and precision medicine research.
The biobanking market in Canada was valued at USD 2.46 billion in 2025. This growth is fueled by country's coordinated national research infrastructure and emphasis on harmonized biospecimen governance across provinces. Canada has developed interconnected biobanking networks that facilitate standardized sample collection, storage, and data sharing for multicenter research projects. Strong focus on population health studies, indigenous health research initiatives, and ethically governed data stewardship frameworks supports increasing utilization of biobanked samples in genomics, epidemiology, and personalized healthcare research.
Asia Pacific: Fastest Growth Driven by Expansion of National Genomics Programs and Rising Biobank Infrastructure Investments
The Asia Pacific biobanking market is expected to grow at a CAGR of 9.46% during the forecast period, showcasing fastest regional growth. This growth is accelerated by increasing government-backed genomics initiatives, expanding biomedical research capabilities, and growing investments in national biorepository infrastructure. Countries across the region are establishing large-scale population health databases linked with biospecimens to support precision medicine. The rising integration of genomic data with healthcare systems is further accelerating demand for advanced biobanking facilities.
The China biobanking market was valued at USD 3.45 billion in 2025, supported by rapid expansion of population-scale genomic databases and increasing investment in precision medicine infrastructure. The country benefits from extensive hospital-based biobank networks integrated with academic research centers and artificial intelligence-driven data platforms. Strong government support for biomedical innovation and increasing demand for locally generated biological datasets are encouraging the development of large biospecimen repositories supporting translational and pharmaceutical research.
The India biobanking market was valued at USD 1.83 billion in 2025, driven by increasing establishment of disease-specific repositories and rising demand for indigenous genomic and epidemiological datasets. Growing focus on studying population diversity, rare genetic disorders, and region-specific disease patterns is driving biospecimen collection activities. According to the Department of Biotechnology, the GenomeIndia project completed whole-genome sequencing of 10,000 individuals, strengthening the country's foundation for large-scale biobanking and precision health research.
The Japan biobanking market was valued at USD 2.26 billion in 2025, supported by strong integration of biobanks with aging population research and long-term cohort studies. The country has developed highly organized biospecimen repositories linked to extensive health records, enabling advanced studies on age-related diseases and personalized healthcare. Sophisticated sample quality standards, robust regulatory frameworks, and increasing utilization of multi-omics research platforms continue to support the expansion of Japan’s biobanking ecosystem.
The biobanking market competitive landscape is moderately fragmented, comprising specialized biobank operators, life science tool providers, laboratory automation companies, cryogenic storage manufacturers, and research institutions. Leading participants compete through advanced sample preservation technologies, automated storage systems, data management platforms, and global biorepository networks. Emerging players focus on digital biobanking, AI-enabled sample analytics, and decentralized data-sharing models. The biobanking market ecosystem is increasingly influenced by precision medicine initiatives, large-scale genomics programs, multi-omics research expansion, and growing demand for high-quality biospecimens supporting translational and clinical research activities.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com